Cargando…
SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
EMPA-REG OUTCOME and CANVAS trials were designed to study the cardiovascular safety of empagliflozin and canagliflozin, respectively. Both studies were sufficiently powered to study the non-inferiority for cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (DM) and showed superio...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688986/ https://www.ncbi.nlm.nih.gov/pubmed/29076040 http://dx.doi.org/10.1007/s13300-017-0320-1 |